Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 8, 2021
Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trialFelix Mahfoud, Michael J Bloch, Michel Azizi, et al.
Hypertension (Dallas, Tex. : 1979)|December 24, 2019
Blood Pressure Control and the Association With Diabetes Mellitus Incidence: Results From SPRINT Randomized TrialChristianne L Roumie, Adriana M Hung, Gregory B Russell, et al.
Alcoholism, Clinical and Experimental Research|January 31, 2006
Alcohol biomarker screening in medical and surgical settingsPeter M Miller, Claudia Spies, Tim Neumann, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trialPeter J Raubenheimer, William C Cushman, Alvaro Avezum, et al.
Cardiovascular Diabetology|August 22, 2022
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetesHertzel C Gerstein, Chinthanie Ramasundarahettige, Alvero Avezum, et al.
Circulation|March 19, 2019
Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO TrialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
American Heart Journal|September 27, 2023
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristicsStephen J Nicholls, Deepak L Bhatt, John B Buse, et al.
Lancet (London, England)|July 3, 2010
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trialFaramarz Ismail-Beigi, Timothy Craven, Mary Ann Banerji, et al.
European Journal of Heart Failure|September 8, 2022
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trialKelley R H Branch, Gilles R Dagenais, Alvaro Avezum, et al.
JAMA Cardiology|November 9, 2022
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical TrialMichel Azizi, Felix Mahfoud, Michael A Weber, et al.
Pageof 11